Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Immunology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Clinical Trials

A listing of Immune (Idiopathic) Thrombocytopenic Purpura (ITP) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (7) clinical trials

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

This is an open-label Phase III extension study to evaluate the long-term safety of eltrombopag in pediatric patients with chronic ITP who previously participated in study TRA115450. This study will allow dosing of eltrombopag at an individualized dose for each subject based upon platelet count. The starting dose will be ...

Phase

Association of Fc RIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

Immune thrombocytopenic purpura (ITP) is a autoimmune disorder in which a decreased number of circulating platelets (thrombocytopenia) manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae). In persons with ITP, platelets are coated with autoantibodies to platelet membrane antigens, ...

Phase

A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.

Rarely children with immune thrombocytopenia purpura (ITP) can present with severe or life-threatening bleeding. In these cases it is very important that the platelet count be raised as quickly as possible. Several studies have shown that IVIG and corticosteroids on their own can raise platelet counts, but few studies have ...

Phase

Multicentre Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with chronic, previously treated ITP. Dosage could be adjusted (2.5~.75 mg/day) to maintain platelet counts 50~250109/L

Phase

A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disease characterized by the presence of platelet autoantibodies, low platelet counts and an increased risk of bleeding. TPO receptor agonists which stimulate platelet production have been shown to be remarkably effective in ITP. Their use as a short-term means of elevating platelet counts ...

Phase

H. Pylori Eradication for Moderate ITP

Current treatment guideline of ITP recommends corticosteroid as the first line treatment when patient has active bleeding or less than 3010^9/L of platelet, because of side effect and cost issues. Since the first case report by Italian study, several investigators have reported that secondary immune thrombocytopenia (ITP) can occur in ...

Phase

The PROLONG Trial - Rituximab Maintenance Therapy in ITP

This is a multi-center, international, randomized, two-phase study: First phase (induction phase) is open-label, hypothesis-generating, involving 1:1 randomization into: rituximab (group 1) or rituximab plus dexamethasone (group 2) to determine if the response to rituximab can be improved by the addition of dexamethasone. Second Phase (maintenance phase) is the main ...

Phase